Traumatic Brain Injury - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Traumatic Brain Injury - Pipeline Review, H1 2017” this report provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.
(EMAILWIRE.COM, June 13, 2017 ) Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.
Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/traumatic-brain-injury-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689371/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
ALSP Inc
Amarantus Bioscience Holdings Inc
Apollo Endosurgery Inc
Athersys Inc
Beech Tree Labs Inc
Cognosci Inc
Eustralis Pharmaceuticals Ltd
Intellect Neurosciences Inc
International Stem Cell Corp
Ischemix Inc
Karyopharm Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Levolta Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
MandalMed Inc
Mapreg SAS
Neuralstem Inc
Neuren Pharmaceuticals Ltd
Neurofx Inc
NeuroNascent Inc
NeuroVive Pharmaceutical AB
New World Laboratories Inc
NuvOx Pharma LLC
Omeros Corp
Oxeia Biopharmaceuticals Inc
PharmatrophiX Inc
Phylogica Ltd
Prevacus Inc
QR Pharma Inc
RegeneRx Biopharmaceuticals Inc
Remedy Pharmaceuticals Inc
Sage Therapeutics Inc
SanBio Inc
STATegics Inc
Stemedica Cell Technologies Inc
SynZyme Technologies LLC
Tetra Discovery Partners LLC
Thera Neuropharma Inc
vasopharm GmbH
VG Life Sciences Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689371/discount
List of Tables
Number of Products under Development for Traumatic Brain Injury, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2017
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H1 2017
Traumatic Brain Injury - Pipeline by Athersys Inc, H1 2017
Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1 2017
Traumatic Brain Injury - Pipeline by Cognosci Inc, H1 2017
Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1 2017
Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1 2017
Traumatic Brain Injury - Pipeline by Ischemix Inc, H1 2017
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Traumatic Brain Injury - Pipeline by MandalMed Inc, H1 2017
Traumatic Brain Injury - Pipeline by Mapreg SAS, H1 2017
Traumatic Brain Injury - Pipeline by Neuralstem Inc, H1 2017
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Neurofx Inc, H1 2017
Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1 2017
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1 2017
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1 2017
Traumatic Brain Injury - Pipeline by Omeros Corp, H1 2017
Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H1 2017
Traumatic Brain Injury - Pipeline by Phylogica Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Prevacus Inc, H1 2017
Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1 2017
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1 2017
Traumatic Brain Injury - Pipeline by SanBio Inc, H1 2017
Traumatic Brain Injury - Pipeline by STATegics Inc, H1 2017
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1 2017
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2017
Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H1 2017
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2017
Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1 2017
Traumatic Brain Injury - Dormant Projects, H1 2017
Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017
Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017
Traumatic Brain Injury - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689371/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.
Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/traumatic-brain-injury-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689371/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
ALSP Inc
Amarantus Bioscience Holdings Inc
Apollo Endosurgery Inc
Athersys Inc
Beech Tree Labs Inc
Cognosci Inc
Eustralis Pharmaceuticals Ltd
Intellect Neurosciences Inc
International Stem Cell Corp
Ischemix Inc
Karyopharm Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Levolta Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
MandalMed Inc
Mapreg SAS
Neuralstem Inc
Neuren Pharmaceuticals Ltd
Neurofx Inc
NeuroNascent Inc
NeuroVive Pharmaceutical AB
New World Laboratories Inc
NuvOx Pharma LLC
Omeros Corp
Oxeia Biopharmaceuticals Inc
PharmatrophiX Inc
Phylogica Ltd
Prevacus Inc
QR Pharma Inc
RegeneRx Biopharmaceuticals Inc
Remedy Pharmaceuticals Inc
Sage Therapeutics Inc
SanBio Inc
STATegics Inc
Stemedica Cell Technologies Inc
SynZyme Technologies LLC
Tetra Discovery Partners LLC
Thera Neuropharma Inc
vasopharm GmbH
VG Life Sciences Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689371/discount
List of Tables
Number of Products under Development for Traumatic Brain Injury, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2017
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H1 2017
Traumatic Brain Injury - Pipeline by Athersys Inc, H1 2017
Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1 2017
Traumatic Brain Injury - Pipeline by Cognosci Inc, H1 2017
Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1 2017
Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1 2017
Traumatic Brain Injury - Pipeline by Ischemix Inc, H1 2017
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Traumatic Brain Injury - Pipeline by MandalMed Inc, H1 2017
Traumatic Brain Injury - Pipeline by Mapreg SAS, H1 2017
Traumatic Brain Injury - Pipeline by Neuralstem Inc, H1 2017
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Neurofx Inc, H1 2017
Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1 2017
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1 2017
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1 2017
Traumatic Brain Injury - Pipeline by Omeros Corp, H1 2017
Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H1 2017
Traumatic Brain Injury - Pipeline by Phylogica Ltd, H1 2017
Traumatic Brain Injury - Pipeline by Prevacus Inc, H1 2017
Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1 2017
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals Inc, H1 2017
Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1 2017
Traumatic Brain Injury - Pipeline by SanBio Inc, H1 2017
Traumatic Brain Injury - Pipeline by STATegics Inc, H1 2017
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1 2017
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2017
Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H1 2017
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2017
Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1 2017
Traumatic Brain Injury - Dormant Projects, H1 2017
Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017
Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017
Traumatic Brain Injury - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689371/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results